Welcome to our dedicated page for Vtv Therapeutics SEC filings (Ticker: VTVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
vTv Therapeutics Inc. filings document the regulatory record of a Nasdaq-listed, late-stage biopharmaceutical company developing oral small-molecule candidates for diabetes and other chronic diseases. Form 8-K reports cover financial results, Regulation FD investor presentations, material agreements, and clinical or regulatory disclosures tied to cadisegliatin and other pipeline assets.
The company’s filings also disclose licensing arrangements involving vTv Therapeutics LLC and HPP737, capital-structure and security-related matters, and governance information in proxy materials. Definitive proxy statements describe board matters, executive compensation, equity awards, shareholder voting items, and related corporate-governance disclosures.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. reported that director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options exercisable into Class A common stock at $35.08 per share. The options vest on the earlier of June 26, 2027 or the 2027 annual shareholder meeting and expire on June 26, 2036.
According to the disclosure, the options were granted to Dr. Cheong in his capacity as a director, but the grant is reported for Baker Bros.–affiliated funds because they hold an indirect proportionate pecuniary interest. The adviser to the funds holds voting and dispositive power over the options and any resulting shares, while Dr. Cheong does not retain compensation rights under adviser policies.
vTv Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. Stockholders elected seven directors, including Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman, each to serve until the 2027 annual meeting or until a successor is elected and qualified.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,964,869 votes for, 1,952 against, and 2,869 abstentions. In addition, they cast a nonbinding advisory vote on executive compensation, with 686,535 votes for, 5,291 against, 1,967,329 abstentions, and 310,535 broker non-votes.
SPIEGELMAN DANIEL K reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. director Daniel K. Spiegelman received a grant of stock options, giving him the right to buy 6,000 shares of Class A Common Stock at $35.08 per share. These options expire on June 26, 2036 and are part of his director compensation.
The options vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, conditioned on his continued board service through vesting. Following this grant, Spiegelman holds options on a total of 16,000 shares.
vTv Therapeutics Inc. director Srinivas Akkaraju received a grant of stock options covering 6,000 shares of Class A common stock. The options have an exercise price of $35.08 per share and expire on June 26, 2036. According to the terms, the award vests on the earlier of June 26, 2027 and the date of the 2027 annual general meeting of shareholders, provided he continues serving on the board. Following this grant, his total directly held option awards reported in this filing increased to 16,983 derivative securities.
vTv Therapeutics Inc. director Fahed Al-Marzooqi received a grant of stock options covering 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options vest on the earlier of June 26, 2027 and the 2027 annual general meeting of shareholders, conditioned on continued board service, and expire on June 26, 2036. Following this grant, his reported derivative holdings tied to this award total 19,555 options.
vTv Therapeutics Inc. director Anne M. Phillips received a grant of options to buy 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These director stock options expire on June 26, 2036 and are part of her board compensation.
The option vests on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, provided she continues serving on the board through that date. Following this grant, she holds options covering 16,860 shares directly.
vTv Therapeutics Inc. is offering up to $47,500,000 of Class A common stock in an at-the-market offering through TD Cowen pursuant to a sales agreement dated previously. Sales may occur from time to time, with TD Cowen acting as agent or principal and receiving a 3.0% commission.
The prospectus supplement assumes for illustration the sale of 1,559,422 shares at the last reported sale price of $30.46 per share and states there were 3,938,654 shares outstanding as of March 31, 2026. Net proceeds are intended for general corporate purposes, including funding development and trials for cadisegliatin.
vTv Therapeutics Inc. filed an 8-K describing an update to its existing at-the-market stock sales program. The company has filed a prospectus supplement with the SEC to increase the number of Class A common shares offered under this program to the full amount allowed by the ATM agreement.
To support these issuances, vTv is also filing a legal opinion from Dechert LLP on the validity of the Class A common stock issuable under the ATM program. This opinion is attached as Exhibit 5.1 and is being incorporated by reference into the company’s effective shelf registration statement on Form S-3.
vTv Therapeutics reported a sharp turnaround in the quarter ended March 31, 2026, driven by licensing revenue. Revenue reached $36.8 million, all from collaboration and license agreements, primarily a $20.0 million upfront payment and additional milestone and license revenue from Newsoara and G42.
Research and development expenses rose to $9.0 million from $2.8 million as the company advanced its lead Type 1 diabetes candidate cadisegliatin and other projects. General and administrative costs increased to $4.6 million. vTv generated net income of $24.1 million, compared with a $6.2 million loss a year earlier.
Cash and cash equivalents grew to $98.1 million from $88.9 million at year-end 2025, helped by the Newsoara payment and recognition of deferred G42 license consideration, giving the company more flexibility to fund ongoing Phase 3 and supporting trials for cadisegliatin and other pipeline work.
vTv Therapeutics Inc. reported a strong turnaround in its first quarter ended March 31, 2026, driven by a major licensing payment. Revenue was $36.8 million, compared with none a year earlier, and net income attributable to shareholders reached $24.1 million versus a prior net loss of $5.1 million.
The company ended the quarter with $98.1 million in cash and cash equivalents and expects this to fund operations through the anticipated topline data readout from its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. An amended license agreement with Newsoara Biopharma added a $20.0 million upfront payment and potential milestones while keeping strategic focus on cadisegliatin.